Jump to Navigation

Abilify Fact Sheet

Printer-friendly version
Medication Name (brand): 
Medication Name (clinical): 

Bristol-Myers Squibb; patent expiration 2014.

  • Schizophrenia

  • Bipolar disorder, manic and mixed episodes.


Partial agonist at the D2 and 5HT 1A receptors, and full antagonist at the 5HT 2A receptor (vs. other atypicals which are D2 and 5 HT 2 antagonists).

  • Supplied as:

  • Oral tablets at 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg
  • Orally disintegrating “Abilify Discmelt” tablets in 10 mg and 15 mg strengths
  • Oral solution (1 mg/mL) in 150 ml bottles
  • Start most patients at 10 mg QD to prevent agitation/akathisia, gradually increase to target dose of 15-30 mg QD.
  • Can be dosed once daily because of long half life.
  • No dosage adjustments required in liver or renal impairment, elderly, or in smokers.

Side Effects: 
  • BLACK BOX WARNING: All atypicals may increase mortality in elderly patients by 1.7 times greater than placebo.

  • Most common are headache, anxiety/agitation/akithisia, insomnia, and nausea. Anecdotally, at 30 mg dose sedation becomes more common.
  • EPS: Minimal risk.
  • Weight gain: Minimal. In clinical trials in schizophrenia there was an average weight gain of about 1.5 pounds over 4-6 weeks, but no weight gain in bipolar patients over 3 weeks.
  • Glucose/Lipids: Minimal to no elevation.
  • EKG: No significant changes; QT interval showed a slight shortening (of no clinical significance).
  • Prolactin level: No elevation.
  • Pregnancy Category C.

Drug-drug Interactions: 
  • Does not itself inhibit liver enzymes, so Abilify does not significantly affect the metabolism of other drugs.

  • Metabolized by CYP2D6 and CYP3A4, so Tegretol will decrease effective dose, while Prozac and Paxil will increase levels. Also, poor metabolizers of CYP2D6 (8% of Caucasians) will have a 60% higher effective dose.


Long half life of 4 days.

Return to issue area